Revolution Medicines to Participate in Upcoming Investor Conferences
RVMD 11.05.2024
About Gravity Analytica
Recent News
- 01.13.2025 - 43rd Annual J.P. Morgan Healthcare Conference
- 01.06.2025 - Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
- 12.05.2024 - Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
Recent Filings
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at Guggenheim's Inaugural Healthcare Innovation Conference and the UBS Global Healthcare Conference.
Details of the company’s participation are as follows:
- Guggenheim's Inaugural Healthcare Innovation Conference
Conference Dates: November 11-13, 2024Fireside Chat Time/Date: 3:00 p.m. ET on Tuesday, November 12, 2024Location: Boston, MA; webcast available
- UBS Global Healthcare Conference
Conference Dates: November 11-14, 2024Fireside Chat Time/Date: 5:00 p.m. ET on Wednesday, November 13, 2024Location: Rancho Palos Verdes, CA; webcast available
To access the live webcasts, please visit the “Events & Presentations” page of Revolution Medicines’ website athttps://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcasts will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.
About Revolution Medicines, Inc.Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552.
Media & Investor Contacts:media@revmed.cominvestors@revmed.com